Publications

Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech J, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker H M, Friedenberg A, Levy-Barda A, Segal A, Broytman Y, Maoz E, Ovadia B, Aharoni Golan M, Shachar E, Ben-Horin S, Maharshak N, Perets TT, Eliakim R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal Tanamy M, Freund NT, Cohen DI and Dotan I. Gastroenterology, 2021

Walking down the memory lane with SARS-CoV-2 B cells

Freund NT, Gerlic M & Croker B. Immunology and Cell Biology, 2021

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

Hagin D*, Freund T*, Navon M*, Adir D, Halperin T, Marom R, Levi I, Benor S, Yifat Y, Ram R and Freund NT. Journal of Allergy and Clinical Immunology (JACI), 2021

Unleashing antibody repones against HIV-1

Ben-Shalom N & Freund NT. Cell Host & Microbe, 2021

Antibodies: what makes us stronger

Freund NT. Human Vaccines and Immunotherapeutics, 2021

Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors

Mor M, Werbner M, Alter L, Safra M, Chomsky E, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, Roitburd-Berman A, Ben Shalom N, Navon M, Rafael D, Sharim H, Kiner E, Griffis E, Gershoni JM, Kobiler O, Lawrynowicz Leibel S, Zimhony O, Carlin AF, Yaari G, Dessau M, Gal-Tanamy M, Hagin D, Croker BA and Freund NT. PLoS Pathogens, 2021

Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature

Munitz, A. Edry‑Botzer L , Itan M, Tur‑Kaspa R, Dicker D, Marcoviciu D, Goren MG , Mor M, Lev S, Gottesman T, Muhsen K, Cohen D, Stein M, Qimron U, Freund NT , Wine Y & Gerlic M. Scientific Reports, 2021

Human antibodies targeting a mycobacterium transporter protein mediate protection against tuberculosis

Watson A, Li H, Ma B, Weiss R, Bendayan D, Abramovich L, Mordekovich M, Pinko E, Bar-Oz M, Wang Z, Du F, Lu Y, Rybniker J, Huang H, Barkan D, Xiang Y, Javid B & Freund NT. Nature Communications, 2021

Structural characterization of a highly-potent V3-targeting broadly neutralizing antibody bound to natively glycosylated HIV-1envelope revealed by an X-ray free electron laser.

Barnes CO, Gristick HB, Freund NT, West Jr. AP, Nussenzweig MC, Bjorkman PJ. Nature Communications, 2018

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.

Medina-Ramirez, Garces F, Escolano A, Skog P, de Taeye S, Moral-Sanchez ID, Dosenovic P, Hua Y, McGuire A, Gitlin A, Woude P, Freund NT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof T, Sliepen K, Blane T, Kootstra N, van Breemen M, Pritchard L, Stanfield R, Crispin M, Ward A, Stamatatos L, Klasse P, ohn Moore J, Nemazee D, Nussenzweig MC, Wilson I, and Sanders RW. Journal of Experimental Medicine, 2017

Asymmetric recognition of HIV-1 Env trimer by V1V2 loop-targeting antibodies

Wang H, Gristick HB, Scharf L, West Jr. AP, Galimidi RP, Seaman MS, Freund NT, Nussenzweig MC. eLife, 2017

Co-existence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

Freund NT, Haoqing H, Scharf L, Noguiera L, Horwitz JA, Sievers S, Sok D, Golijanin J, Halper-Stromberg A, West A, Lorenzi JC, Toth I, Piechocka-Torcha A, Wang LX, Seaman MS, Burton D, Gazumyan A, Walker BD, Bjorkman PJ & Nussenzweig MC. Science Translational Medicine, 2017

Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knock in mice

Escolano A, Steichen J, Dosenovic P, Kulp D, Golijanin J, Sok D, Freund NT, Araki T, Lowe S, Chen S, Heinemann J, Oliveira T, Gitlin A, Hui-Yao K, Georgeson E, Karen L, Francisco S, Gazumyan A, Burton D, Schief WR, Nussenzweig MC. Cell, 2017

HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies

Steichen J.M, Kulp D.W, Tokatlian, T, Escolano A, Docenovic, P, Stanfield RL, McCoy L.E, Ozorowski G, Xiaozhen H, Kalyuzhniy, O, Briney B, Schiffner T, 0arces F, Freund NT, Gitlin, A, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan A, Yun D.S, Mayer C, Ward A, Burton D, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR. Immunity, 2016

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice

McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L. Nature Communications, 2016

A New glycan-dependent CD4-binding site neutralizing antibody exerts pressure on HIV-1 in vivo

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC. PLoS Pathogens, 2015

Reconstitution of the receptor-binding motif of the SARS coronavirus

Freund NT, Roitburd-Berman A, Sui J, Marasco WA, Gershoni JM. Protein Engineering, Design and Selection, 2015

Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient

Freund NT, Scheid JF, Mouquet H, Nussenzweig MC. Journal of Immunological Methods, 2015

Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao KH, Liu C, Gazumyan A, Seaman MS, Björkman PJ, Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC. Cell, 2016

Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides

Tarnovitski N, Matthews JL, Sui J, Gershoni MJ. Journal of Molecular Biology, 2006